P2B001
Pharma Two B
[]
pharma two b to present additional positive results from p2b001 phase 3 trial at 2023 american academy of neurology annual meeting - showed p2b001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable ef... 
CEO Of Digital Media Online